
How OCALIVA Revolutionizes Treatment for NASH Patients
Obeticholic acid, marketed as OCALIVA, emerges as a promising therapy for nonalcoholic steatohepatitis (NASH), a progressive liver disease primarily managed by weight loss and lifestyle changes. Understanding OCALIVA’s mechanism as a farnesoid X receptor agonist, its efficacy in clinical trials, potential side effects, and cost-effectiveness considerations is important. Explore the current landscape and future directions […]
3 minute read